CAR-T cell therapy for hard-to-treat autoimmune blood diseases
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This early-stage trial tests a new type of immune cell therapy (CAR-T) that targets two proteins, CD19 and BCMA, in people with autoimmune blood diseases like ITP, AIHA, or Evans syndrome that have not responded to standard treatments. It aims to reset the immune system and reduce production of harmful antibodies.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You have a confirmed autoimmune blood disease (like ITP, AIHA, or Evans syndrome) that has lasted at least 6 months.
- You have tried at least 2–3 standard treatments, and they did not work well or you cannot take them anymore.
- Your organ function (heart, kidneys, liver) must be good enough, as shown by specific lab tests.
- You must not have certain infections (like HIV, hepatitis) or other serious health conditions (like recent heart problems or tumors).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new kind of cell therapy (UCAR-T) that targets CD19 and BCMA proteins on immune cells. It is for people with certain neurological autoimmune diseases like multiple sclerosis, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, or autoimmune encephalitis who have not responded well to standard treatments.
This trial tests a new CAR-T cell therapy that targets two proteins (CD19 and BCMA) on immune cells. It's designed for people with certain autoimmune diseases like lupus, scleroderma, vasculitis, myositis, or Sjögren's syndrome that are not controlled by standard treatments.
This trial tests a special type of therapy called CAR-T cells, which are made from the patient's own blood cells and are designed to help control severe autoimmune diseases that haven't improved with other treatments. It is for children and young adults aged 5 to 19 with certain conditions like lupus, scleroderma, or myositis.
This study tests a new cell therapy called CAR-T (using your own immune cells) for people with severe autoimmune diseases like lupus, scleroderma, or myositis that have not improved with standard treatments. The goal is to see if it can safely reduce disease activity.
This early-stage trial tests a new type of cell therapy (CAR-T cells) designed to treat severe autoimmune diseases where the immune system attacks the body's own organs. The therapy targets specific immune cells (B cells) that may be causing the disease. It may help patients who haven't improved with standard treatments or can't tolerate them.
This study tests a type of immunotherapy called CAR-T for people with certain autoimmune diseases that have not responded to standard treatments. It aims to see if this cell therapy can calm the overactive immune system.
Hear when a new Autoimmune Hemolytic Anemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.